|Bid||81.10 x 1000|
|Ask||81.15 x 800|
|Day's Range||80.88 - 81.48|
|52 Week Range||68.44 - 84.56|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||29.31|
|Earnings Date||Oct 28, 2021|
|Forward Dividend & Yield||2.60 (3.45%)|
|Ex-Dividend Date||Sep 14, 2021|
|1y Target Est||93.21|
Earlier this month, Merck (NYSE: MRK) announced it was ending clinical trials of its antiviral pill candidate for treating COVID-19, molnupiravir, on account of the potential therapy's high level of effectiveness. Take Gilead Sciences' (NASDAQ: GILD) antiviral drug, remdesivir. Will Merck's drug follow a similar or better path?
In this article, we discuss the 11 best dividend stocks to buy according to Warren Buffett. You can skip our detailed analysis of Buffett’s hedge fund and his investment philosophy and go directly to read the 5 Best Dividend Stocks To Buy According To Warren Buffett. Warren Buffett is an American businessman, investor, and CEO […]
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.